Search

e15701Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare disease whose therapy of choice is cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (...

PurposeThis multi-institutional registry study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (DMPM).Patients and MethodsA multi-institutional data registry that included 405 patients with DMPM treated by a uniform approach that used CRS and HIPEC was established. The primary end point was overall survival. The secondary end point was evaluation of prognostic variables for overall survival.ResultsFollow-up was complete in 401 patients (99%). The median follow-up period for the patients who were alive was 33 months (range, 1 to 235 months). The mean age was 50 years (standard deviation [SD], 14 years). Three hundred eighteen patients (79%) had epithelial tumors. Twenty-five patients (6%) had positive lymph nodes. The mean peritoneal cancer index was 20. One hundred eighty-seven patients (46%) had complete or near-complete cytoreduction. Three hundred seventy-two patients (92%) received HIPEC. One hundred twenty-seven patients (31%) had grades 3 to 4 complications. Nine patients (2%) died perioperatively. The mean length of hospital stay was 22 days (SD, 15 days). The overall median survival was 53 months (1 to 235 months), and 3- and 5-year survival rates were 60% and 47%, respectively. Four prognostic factors were independently associated with improved survival in the multivariate analysis: epithelial subtype (P < .001), absence of lymph node metastasis (P < .001), completeness of cytoreduction scores of CC-0 or CC-1 (P < .001), and HIPEC (P = .002).ConclusionThe data suggest that CRS combined with HIPEC achieved prolonged survival in selected patients with DMPM.

TPS3653 Background: In locally advanced rectal cancer (LARC), local recurrence is uncommon with good quality total mesorectal excision (TME) allowing preoperative chemo-radiotherapy (PCRT) to be om...

4033 Background: We built nomograms for predicting overall (OS) and progression-free survivals (PFS) in patients with pseudomyxoma peritonei (PMP) treated with cytoreductive surgery (CRS)+/-intraperitoneal chemotherapy (IPCT). Methods: Data from 1,715 PMP patients in 31 centers from 1993 to 2012 constituted the developing set. The covariates were previous systemic chemotherapy (sCT), histologic subtype (Ronnett’s criteria), peritoneal cancer index (PCI), completeness of cytoreduction (CC), IPCT (Hyperthermic intraperitoneal chemotherapy [HIPEC], early postoperative chemotherapy [EPIC], or both), lymph node status (LN), G3-5 morbidity (NCI CTCAE v3), and surgical proficiency. Centers with >100 procedures for PMP were considered proficient. Continuous variables were transformed using restricted cubic splines. We handled missing data using multiple imputation with chained equations (MICE) approach. We fitted a Cox model in each of the different completed developing datasets generated by MICE. Pooled estimate...